User menu

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.

Bibliographic reference Warrender-Sparkes, Matthew ; Spelman, Tim ; Izquierdo, Guillermo ; Trojano, Maria ; Lugaresi, Alessandra ; et. al. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.. In: Multiple Sclerosis Journal, Vol. 22, no.4, p. 520-32 (2016)
Permanent URL http://hdl.handle.net/2078.1/181825
  1. Wingerchuk Dean M., Carter Jonathan L., Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies, 10.1016/j.mayocp.2013.11.002
  2. Filippini Graziella, Del Giovane Cinzia, Vacchi Laura, D'Amico Roberto, Di Pietrantonj Carlo, Beecher Deirdre, Salanti Georgia, Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis, 10.1002/14651858.cd008933.pub2
  3. Tan Hiangkiat, Cai Qian, Agarwal Sonalee, Stephenson Judith J., Kamat Siddhesh, Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis, 10.1007/s12325-010-0093-7
  4. Kalincik Tomas, Spelman Timothy, Trojano Maria, Duquette Pierre, Izquierdo Guillermo, Grammond Pierre, Lugaresi Alessandra, Hupperts Raymond, Cristiano Edgardo, Van Pesch Vincent, Grand’Maison Francois, La Spitaleri Daniele, Rio Maria Edite, Flechter Sholmo, Oreja-Guevara Celia, Giuliani Giorgio, Savino Aldo, Amato Maria Pia, Petersen Thor, Fernandez-Bolanos Ricardo, Bergamaschi Roberto, Iuliano Gerardo, Boz Cavit, Lechner-Scott Jeannette, Deri Norma, Gray Orla, Verheul Freek, Fiol Marcela, Barnett Michael, van Munster Erik, Santiago Vetere, Moore Fraser, Slee Mark, Saladino Maria Laura, Alroughani Raed, Shaw Cameron, Kasa Krisztian, Petkovska-Boskova Tatjana, Braber-Moerland Leontien den, Chapman Joab, Skromne Eli, Herbert Joseph, Poehlau Dieter, Needham Merrilee, Bacile Elizabeth Alejandra Bacile, Arruda Walter Oleschko, Paine Mark, Singhal Bhim, Vucic Steve, Cabrera-Gomez Jose Antonio, Butzkueven Helmut, , Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis, 10.1371/journal.pone.0063480
  5. Jokubaitis Vilija G., Spelman Tim, Lechner-Scott Jeannette, Barnett Michael, Shaw Cameron, Vucic Steve, Liew Danny, Butzkueven Helmut, Slee Mark, on behalf of the Australian MSBase Study Group, The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform, 10.1371/journal.pone.0059694
  6. Halpern Rachel, Agarwal Sonalee, Borton Leigh, Oneacre Kathy, Lopez-Bresnahan Maria V., Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: Retrospective claims analysis, 10.1007/s12325-011-0054-9
  7. Halpern Rachel, Agarwal, Dembek Carole, Borton, Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis, 10.2147/ppa.s15702
  8. Reynolds Matthew W., Stephen Reejis, Seaman Chris, Rajagopalan Kitty, Persistence and adherence to disease modifying drugs among patients with multiple sclerosis, 10.1185/03007990903554257
  9. Kleinman Nathan L., Beren Ian A., Rajagopalan Krithika, Brook Richard A., Medication adherence with disease modifying treatments for multiple sclerosis among US employees, 10.3111/13696998.2010.527588
  10. Río Jordi, Porcel Joana, Téllez Nieves, Sánchez-Betancourt Angela, Tintoré M ar, Arévalo M Jesús, Nos Carlos, Montalban Xavier, Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis, 10.1191/1352458505ms1173oa
  11. Portaccio E., Zipoli V., Siracusa G., Sorbi S., Amato M.P., Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis, 10.1159/000111875
  12. Cohen Jeffrey A., Barkhof Frederik, Comi Giancarlo, Izquierdo Guillermo, Khatri Bhupendra, Montalban Xavier, Pelletier Jean, Eckert Benjamin, Häring Dieter A., Francis Gordon, Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS, 10.1007/s00415-013-6932-0
  13. Kappos Ludwig, Radue Ernst-Wilhelm, O'Connor Paul, Polman Chris, Hohlfeld Reinhard, Calabresi Peter, Selmaj Krzysztof, Agoropoulou Catherine, Leyk Malgorzata, Zhang-Auberson Lixin, Burtin Pascale, A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis, 10.1056/nejmoa0909494
  14. Khatri Bhupendra, Barkhof Frederik, Comi Giancarlo, Hartung Hans-Peter, Kappos Ludwig, Montalban Xavier, Pelletier Jean, Stites Tracy, Wu Stacy, Holdbrook Fred, Zhang-Auberson Lixin, Francis Gordon, Cohen Jeffrey A, Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study, 10.1016/s1474-4422(11)70099-0
  15. Agashivala Neetu, Wu Ning, Abouzaid Safiya, Wu You, Kim Edward, Boulanger Luke, Brandes David W, Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study, 10.1186/1471-2377-13-138
  16. Oleen-Burkey MerriKay, Cyhaniuk Anissa, Swallow Eric, Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years, 10.3111/13696998.2013.764309
  17. Butzkueven H, Chapman J, Cristiano E, Grand’Maison F, Hoffmann M, Izquierdo G, Jolley D, Kappos L, Leist T, Pöhlau D, Rivera V, Trojano M, Verheul F, Malkowski J-P, MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis, 10.1177/1352458506070775
  18. Prinja Shankar, Gupta Nidhi, Verma Ramesh, Censoring in clinical trials: Review of survival analysis techniques, 10.4103/0970-0218.66859
  19. Box-Steffensmeier Janet M., De Boef Suzanna, Repeated events survival models: the conditional frailty model, 10.1002/sim.2434
  20. Meyniel Claire, Spelman Timothy, Jokubaitis Vilija G., Trojano Maria, Izquierdo Guillermo, Grand’Maison François, Oreja-Guevara Celia, Boz Cavit, Lugaresi Alessandra, Girard Marc, Grammond Pierre, Iuliano Gerardo, Fiol Marcela, Cabrera-Gomez Jose Antonio, Fernandez-Bolanos Ricardo, Giuliani Giorgio, Lechner-Scott Jeannette, Cristiano Edgardo, Herbert Joseph, Petkovska-Boskova Tatjana, Bergamaschi Roberto, van Pesch Vincent, Moore Fraser, Vella Norbert, Slee Mark, Santiago Vetere, Barnett Michael, Havrdova Eva, Young Carolyn, Sirbu Carmen-Adella, Tanner Mary, Rutherford Michelle, Butzkueven Helmut, , Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome, 10.1371/journal.pone.0038661
  21. O'Rourke K ET, Hutchinson M, Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns, 10.1191/1352458505ms1131oa
  22. Tremlett H. L., Oger J., Interrupted therapy: Stopping and switching of the  -interferons prescribed for MS, 10.1212/01.wnl.0000078885.05053.7d
  23. Bonafede Machaon M., Johnson Barbara H, Wenten Madé, Watson Crystal, Treatment Patterns in Disease-Modifying Therapy for Patients With Multiple Sclerosis in the United States, 10.1016/j.clinthera.2013.07.330
  24. Rudick Richard A., Stuart William H., Calabresi Peter A., Confavreux Christian, Galetta Steven L., Radue Ernst-Wilhelm, Lublin Fred D., Weinstock-Guttman Bianca, Wynn Daniel R., Lynn Frances, Panzara Michael A., Sandrock Alfred W., Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis, 10.1056/nejmoa044396
  25. Kalincik Tomas, Horakova Dana, Spelman Tim, Jokubaitis Vilija, Trojano Maria, Lugaresi Alessandra, Izquierdo Guillermo, Rozsa Csilla, Grammond Pierre, Alroughani Raed, Duquette Pierre, Girard Marc, Pucci Eugenio, Lechner-Scott Jeannette, Slee Mark, Fernandez-Bolanos Ricardo, Grand'Maison Francois, Hupperts Raymond, Verheul Freek, Hodgkinson Suzanne, Oreja-Guevara Celia, Spitaleri Daniele, Barnett Michael, Terzi Murat, Bergamaschi Roberto, McCombe Pamela, Sanchez-Menoyo Jose, Simo Magdolna, Csepany Tunde, Rum Gabor, Boz Cavit, Havrdova Eva, Butzkueven Helmut, , Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis : Natalizumab vs Fingolimod, 10.1002/ana.24339
  26. Spelman Timothy, Kalincik Tomas, Zhang Annie, Pellegrini Fabio, Wiendl Heinz, Kappos Ludwig, Tsvetkova Larisa, Belachew Shibeshih, Hyde Robert, Verheul Freek, Grand-Maison Francois, Izquierdo Guillermo, Grammond Pierre, Duquette Pierre, Lugaresi Alessandra, Lechner-Scott Jeannette, Oreja-Guevara Celia, Hupperts Raymond, Petersen Thor, Barnett Michael, Trojano Maria, Butzkueven Helmut, , Comparative efficacy of switching to natalizumab in active multiple sclerosis, 10.1002/acn3.180
  27. Jokubaitis Vilija G., Spelman Tim, Kalincik Tomas, Izquierdo Guillermo, Grand'Maison François, Duquette Pierre, Girard Marc, Lugaresi Alessandra, Grammond Pierre, Hupperts Raymond, Cabrera-Gomez José, Oreja-Guevara Celia, Boz Cavit, Giuliani Giorgio, Fernández-Bolaños Ricardo, Iuliano Gerardo, Lechner-Scott Jeannette, Verheul Freek, van Pesch Vincent, Petkovska-Boskova Tatjana, Fiol Marcela, Moore Fraser, Cristiano Edgardo, Alroughani Raed, Bergamaschi Roberto, Barnett Michael, Slee Mark, Vella Norbert, Herbert Joseph, Shaw Cameron, Saladino Maria Laura, Amato Maria Pia, Liew Danny, Paolicelli Damiano, Butzkueven Helmut, Trojano Maria, , Predictors of disability worsening in clinically isolated syndrome, 10.1002/acn3.187
  28. Tarrants M, Mult Scler Int, 2011 (2011)